Appointment of Joint Corporate Broker

RNS Number : 9190N
MaxCyte, Inc.
03 February 2021

MaxCyte, Inc.

("MaxCyte" or the "Company") 


Appointment of Joint Corporate Broker


Gaithersburg, Maryland - 3 February 2021: MaxCyte (LSE: MXCT, MXCL), a global cell-engineering and life sciences company, announces the appointment of Stifel Nicolaus Europe Limited as the Company's Joint Corporate Broker with immediate effect alongside existing Joint Corporate Brokers Panmure Gordon and Numis.



+1 301 944 1660

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer




Nominated Adviser and Joint Corporate Broker

Panmure Gordon (UK) Limited

Emma Earl / Freddy Crossley (Corporate Finance)

Rupert Dearden (Corporate Broking)


Joint Corporate Broker

Numis Securities Ltd.

James Black / Duncan Monteith / Matthew O'Dowd


Joint Corporate Broker

+44 (0) 20 7886 2892





+44 (0) 20 7260 1000


Stifel Nicolaus Europe Limited

Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking)

Nick Adams (Corporate Broking)

+44 (0) 20 7710 7600


Financial PR Adviser

Consilium Strategic Communications


+44 (0)203 709 5700

Mary-Jane Elliott / Chris Welsh





About MaxCyte

MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Company's technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into twelve clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100